References
- Lefaucheur C, Louis K, Morris AB, et al. Clinical recommendations for posttransplant assessment of anti–HLA (Human Leukocyte Antigen) donor-specific antibodies: A Sensitization in Transplantation: Assessment of Risk consensus document. American Journal of Transplantation 2023; 23(1):115–132.
- Wiebe C, Gareau AJ, Pochinco D, et al. Evaluation of C1q Status and Titer of De Novo DonorSpecific Antibodies as Predictors of Allograft Survival. Am J Transplant 2017; 17(3):703–711.
- Ranganathan D, John GT. Therapeutic Plasma Exchange in Renal Disorders. Indian J Nephrol. 2019; 29(3):151–159.
- Geneugelijk K, Spierings E. PIRCHE-II: an algorithm to predict indirectly recognizable HLA epitopes in solid organ transplantation. Immunogenetics. 2020; 72(1–2):119–129.
- Geneugelijk K, Niemann M, Drylewicz J, et al. PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Front Immunol. 2018; 9:321.
- Spitznagel T, Matter LS, Kaufmann YL, et al. PIRCHE-II scores prove useful as a predictive biomarker among kidney transplant recipients with rejection: An analysis of indication and follow-up biopsies. Front Immunol. 2022; 13:949–933.
- Geneugelijk K, Spierings E. Matching donor and recipient based on predicted indirectly recognizable human leucocyte antigen epitopes. Int J Immunogenet 2018; 45(2):41–53.
- Lachmann N, Niemann M, Reinke P, et al. Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo DonorSpecific HLA Antibodies Following Renal Transplantation. Am J Transplant 2017; 17(12):3076–3086.
- Claas FHJ, Dankers MK, Oudshoorn M, et al. Differential immunogenicity of HLA mismatches in clinical transplantation. Transpl Immunol 2005; 14(3–4):187–91.
- Doxiadis II, Smits JM, Schreuder GM, et al. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet 1996; 348(9031):850–853.
- Kawase T, Morishima Y, Matsuo K, et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007; 110(7):2235–2241.
- Kawase T, Matsuo K, Kashiwase K, et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113(12):2851–28518.
- Wiebe C, Pochinco D, Blydt-Hansen TD, et al. Class II HLA epitope matching-a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013; 13:3114–3122.
- Geneugelijk K, Thus KA, Spierings E. Predicting alloreactivity in transplantation. J Immunol Res 2014; 2014:1–12.
- Jackson KR, Chen J, Kraus E, et al. Outcomes of cPRA 100% deceased donor kidney transplant recipients under the new Kidney Allocation System: A single-center cohort study. Am J Transplant 2020; 20(10):2890–2898.
- Kausman JY, Walker AM, Cantwell LS, et al. Application of an epitope-based allocation system in pediatric kidney transplantation. Pediatr Transplant 2016; 20:931.